Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-188E DNA vaccine, GX-I7 and nivolumab in HPV16/18-positive recurrent or metastatic head and neck cancer
KCT0007102Phase 2Recruiting
- Sponsor
- Genexine
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid, efineptakin alfa, nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Genexine. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on KCT0007102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007102.